GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
Ting Liu,
Xue-feng Kan,
Charlie Ma,
Li-li Chen,
Tian-tian Cheng,
Zhen-wei Zou,
Yong Li,
Feng-jun Cao,
Wen-jie Zhang,
Jing Yao,
Pin-dong Li
Affiliations
Ting Liu
Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xue-feng Kan
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Charlie Ma
The Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Li-li Chen
The Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Tian-tian Cheng
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
Zhen-wei Zou
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Yong Li
Cancer Center, Renmin Hospital, Hubei University of Medicine, Shiyan, China
Feng-jun Cao
Cancer Center, Renmin Hospital, Hubei University of Medicine, Shiyan, China
Wen-jie Zhang
Department of Pathology, Shihezi University School of Medicine, Shihezi, China
Jing Yao
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Pin-dong Li
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Glutathione peroxidase 2 has important role of tumor progression in lots of carcinomas, yet little is known about the prognosis of glutathione peroxidase 2 in hepatocellular carcinoma. Glutathione peroxidase 2 expression was assessed by immunohistochemistry in hepatocellular carcinoma tissues. The association between glutathione peroxidase 2 expression with clinicopathological/prognostic value was examined. Glutathione peroxidase 2 overexpression was correlated with alpha-fetoprotein level, larger tumor, BCLC stage, and tumor recurrence. Kaplan–Meier analysis showed that glutathione peroxidase 2 was an independent predictor for overall survival and time to recurrence. glutathione peroxidase 2 overexpression was correlated with poor prognosis in patient subgroups stratified by tumor size, differentiation, tumor–node–metastasis, and BCLC stage. Moreover, stratified analysis showed that tumor–node–metastasis stage-I patients with high glutathione peroxidase 2 expression had poor prognosis than those with low glutathione peroxidase 2 expression. Additionally, combination of glutathione peroxidase 2 and serum alpha-fetoprotein was correlated with prognosis in hepatocellular carcinoma. In conclusion, glutathione peroxidase 2 overexpression contributes to poor prognosis of hepatocellular carcinoma patients and helps to identify the high-risk hepatocellular carcinoma patients.
